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Abstract 
 
Background: Type II diabetes and major depression are both considered epidemics in the United States, 
with a high rate of comorbidity. Although the diseases have a physiological connection, western medicine 
still treats them separately,  with  medications  that  often exacerbate the other  condition  and  come  with 
debilitating side effects. Exercise has been shown to be an effective treatment modality for both diseases 
separately, however, no research has been done on exercise as a treatment or preventative measure for the 
comorbidity of the two conditions. 
Aim:  The  purpose  of  this  study  is  to  provide  a  comprehensive  review  of  the  literature  regarding  the 
efficacy of exercise for the treatment and prevention of comorbid type II diabetes and major depression.   
Methodology: Academic Search Primere, Pubmed, Medline and Google Scholar were used to find sources. 
Search terms such as “type II diabetes, depression, exercise” were used. Sixty three studies were deemed 
appropriate for this literature review. 
Results: Results indicate that exercise is effective at treating type II diabetes and major depression, and 
would also be effective at preventing the comorbidity of the two. Pharmaceuticals commonly used to treat 
the two diseases bring with them unwanted side effects which are often more debilitating than the original 
pathology, whereas side effects of exercise tend to be beneficial to one’s health. 
Conclusions: Exercise is an effective way to prevent comorbidity of major depression and type II diabetes 
without unwanted side effects. It should be implemented as the front line treatment for both type II diabetes 
and depression. 
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Introduction 
 
Type II diabetes and major depression could be 
considered two of the most severe epidemics in 
the  United  States,  considering  that  type  II 
diabetes affects over eight percent of the U.S. 
population, and major depression affects around 
nine  percent.  Although  both  diseases  are 
chronic and debilitating, current treatments for 
these  conditions  are  limited,  consisting 
predominantly  of  pharmaceutical  medications 
which  treat  the  symptoms  as  opposed  to  the 
etiology.  This  symptomatic  treatment  is  more 
appropriate  for  short  term,  acute  illness,  not 
long-term diseases such as these; mainly due to 
the compounding effect of pharmaceuticals.  
This  compounding  effect  is  defined  as  the 
process  by  which  chronic  disease  sufferers 
build tolerances to medications and have to take 
continually  larger  and  larger  doses  to  keep 
getting  positive  results.  This  leads  to  a 
concurrent compounding of side effects as well 
as increased risk of drug interactions (Boulton, 
2005).  
Lifetime  prevalence  of  depression  in  type  II 
diabetes  has  been  found  to  be  as  high  as  30 
percent (Marcus et al., 1992). A meta-analysis 
preformed by Anderson, Clouse, Freedland and 
Lustman  (2001),  provided  evidence  that  even 
when  gender,  geographic  area,  diagnostic 
criteria  for  depression,  and  type  of  diabetes 
were  controlled  for  the  prevalence  of www.inernationaljournalofcaringsciences.org 
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depression  was  twice  as  high  in  those  with 
diabetes compared to those without diabetes.  
Although  theoretical  mechanisms  connecting 
the occurrence of depression in type II diabetics 
have yet to be defined, one theory has proposed 
that  the  social  stigmatisms  and the  burden  of 
having  a  chronic  disease  contribute 
significantly to the risk of depression (Talbot & 
Nouwen,  2000).  Not  only  this,  but  the 
complications that arise from type  II diabetes 
are virtually unavoidable and tend to get worse 
with time. 
Despite type II diabetes and depression having 
been shown to be linked both theoretically and 
physiologically (Lustman et al., 2000; Lustman 
et  al.,  1997;  Lustman,  Griffith,  Freedland, 
Kissel  &  Clouse,  1988),  common  medicinal 
practices  treat  them  as  separate  pathologies. 
Often,  treatments  for  one  condition  not  only 
disregard,  but  exacerbate  the  other  or  cause 
additional  problems  unrelated  to  the  original 
pathology.  
Most current pharmaceutical treatments provide 
only acute relief from symptoms and do nothing 
to ameliorate the chronic effects because they 
do  not  address  the  etiology  of  the  condition. 
Although  diabetics  often  take  insulin,  which 
treats  the  cause  of  the  symptoms,  taking 
prescription  insulin  does  not  address  the 
problem that causes lack of insulin production 
in the body in the first place. This makes most 
pharmaceuticals unsuitable for chronic diseases 
such as type II diabetes and major depression, 
especially  when  the  comorbidity  of  the  two 
diseases is so common. Not only this, but the 
continuous  use  of  pharmaceuticals  creates  a 
lifestyle  that  is  increasingly  reliant  on 
medication. 
With  the  prevalence  of  both  diseases  rising, 
there  is  clear  need  for  new  treatment 
approaches that decrease the risk for comorbid 
conditions. It has been suggested that one of the 
most  effective  ways  to  treat  both  these 
conditions  simultaneously,  without  negative 
side  effects,  is  lifestyle  changes,  such  as 
increased  exercise  (Campbell  &  Campbell, 
2004;  Mezuk,  Eaton,  Albrecht  &  Golden, 
2008).  Though  implementing  lifestyle 
interventions  is  much  more  difficult  than 
pharmaceuticals,  they  are  the  only  way  in 
which both type II diabetics and those suffering 
from  major  depression  will  be  able  to  find 
effective, life long solutions for the condition, 
and  prevent  comorbidity.  Exercise  has  been 
shown to be effective at treating type II diabetes 
and  major  depression  separately  (Roth  & 
Holmes,  1987;  Sigal  et  al.,  2007;  Steptoe, 
Edwards, Moses & Mathews, 1989), but there 
is  limited  research  regarding  the  effects  of 
exercise  on  the  two  diseases  together.  The 
purpose  of  this  study  is  to  provide  a 
comprehensive  review  of  the  literature 
supporting and refuting the efficacy of exercise 
for  the  treatment  and  prevention  of  comorbid 
type II diabetes and major depression. 
 
Methods 
 
Academic  Search Premiere,  Pubmed,  Medline 
and Google Scholar were used to find sources 
for this literature review. Search terms such as 
“type  2  diabetes,  major  depression,  exercise” 
and  combinations  thereof  were  used  in 
conjunction  with  such  words  as,  “effects  of, 
treatment  of,  and,  cormorbid”.  Centers  for 
Disease  Control  and  Prevention  and  National 
Health  Institute  websites  were  searched  for 
relevant  information  regarding  the  respective 
diseases. Literature found to be irrelevant to the 
prevalence  or  treatment  of  either  type  II 
diabetes  or  major  depression  was  excluded. 
Studies regarding the etiology, prevalence and 
treatment of type II diabetes were analyzed and 
reviewed,  followed  by  studies  regarding  the 
etiology,  prevalence  and  treatment  of  major 
depression.  Finally,  literature  supporting  and 
refuting  the  connection  between  the  two 
conditions  was  reviewed  and  followed  by  a 
review of the literature supporting and refuting 
the use of exercise as a treatment modality for 
both  conditions,  separately  and  comorbidly. 
Only peer-reviewed literature was used in this 
review,  unless  opinions  or  consumer  reports 
specifically relating to the topic were deemed 
necessary in order to understand the impact on 
a  more  personal  level.  A  total  of  63  studies 
were used in this literature review. 
 
Comorbidity 
 
When one examines the etiology and symptoms 
of type II diabetes and major depression, they 
do not appear to be connected. However, type II www.inernationaljournalofcaringsciences.org 
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diabetics  have  twice  as  high  of  a  risk  of 
developing depression as those without, with a 
lifetime  prevalence  of  30  percent  (Anderson, 
Freedland, Clouse & Lustman, 2001; Marcus et 
al., 1992).  
Persons  with  psychiatric  disorders  generally 
have more risk factors for developing type II 
diabetes  when  compared  to  those  without, 
especially  physical  inactivity,  sedentary 
lifestyle, unhealthy dietary choices, and obesity 
(Hayward, 1995). Even when no other diabetic 
risk factors are evident, those with depression 
appear to have higher concentrations of blood 
glucose  (Winokur,  Maislin,  Phillips  & 
Amsterdam, 1988). This could be attributed to 
the  idea  that  poor  glycemic  control  and 
increased  depressive  symptoms  have  a 
positively  correlated  relationship. 
Improvements in depression have been shown 
to result in improvements in glycemic control 
(Lustman  et  al.,  1997;  Lustman,  Griffith, 
Freedland, Kissel& Clouse, 1988). This would 
imply that mood and behavior could have some 
effect over the severity of the diabetes and the 
rate  at  which  the  complications  accelerate. 
Research  also  suggests that  serotonin may  be 
associated  with  physical  health  as  well  as 
mood.  In  a  study  with  otherwise  healthy 
subjects,  low  serotonin  was  associated  with 
metabolic  syndrome  and  heart  disease 
(Muldoon  et  al.,  2004),  indicating  that  those 
with  low  serotonin  may  be  at  risk  for  poor 
physical as well as mental functioning (Young, 
2007). Lower than normal serotonin levels have 
also  been  cited  as  a  main  cause  of  major 
depression.  This  indicates  that  low  serotonin 
levels,  which  are  also  associated  with  poor 
glycemic  control  could  be  a  physiological 
connection  between  type  II  diabetes  and 
depression. Not only this, but some of the most 
common  side  effects  of  antidepressants  are 
weight  gain,  hypertension,  metabolism 
inhibition, changes in appetite and somnolence, 
all  of  which  increase  risks  of  adipose  tissue 
build  up  and  insulin  resistance,  leading  to 
diabetes  (Boulton,  2005;  Sheehan,  2005; 
Consumer  Reports  Best  Buy  Drugs,  2011; 
Remick, Froese & Keller, 1989; Stahl, Grady, 
Moret & Briley, 2005; Wamboldt & Kapustin, 
2006). 
In a study by Golden et al. (2008), those being 
treated for type II diabetes showed up to an 86 
percent higher chance of developing depression 
when  compared  to  the  control  subjects,  with 
normal  glucose  levels.  However,  those  with 
untreated  type  II  diabetes  were  actually  at  a 
decreased risk of depression when compared to 
controls. The same held true with pre-diabetics; 
the odds of those with impaired glucose levels 
developing  depression  were  20  percent  lower 
than  their  control  counterparts.  This  outcome 
could  have  many  explanations,  but  the  most 
potentially serious one would be that treatment 
for type II diabetes is possibly one of the main 
causes of the elevated risk of depression in type 
II  diabetics.  These  results  show  that  those 
diagnosed  with  type  II  diabetes  who  weren’t 
being  treated  had  a  decreased  chance  of 
developing  depressive  symptoms,  where  as 
those who were being treated had as much as 86 
percent  higher  odds  of  developing  depression 
once lifestyle and socioeconomic variables had 
been  accounted  for.  Depending  on  how 
advanced the diabetes is, there could be a dozen 
different  complications  accompanying  the 
disease. Each complication carries with it added 
medication and treatments, and each medication 
also  incurs  its  own  complications  and  extra 
needed  alleviations.  Golden  et  al.  (2008) 
suggest  that  the  psychological  stress  of 
managing  type  II  diabetes  may  induce 
depressive symptoms. It is also mentioned that 
treated  type  II  diabetes  may  have  a  greater 
number of complications or comorbidities than 
those  going  untreated.  This  theory  of 
complications causing depression is supported 
in  previous  literature;  higher  levels  of 
depression have been associated with common 
complications  such  as  neuropathy  and 
retinopathy  (Geringer,  Perlmuter,  Stern  & 
Nathan,  1988;  Miyaoka,  Miyaoka,  Motomiya, 
Kitamura & Asia, 1997).  
A  meta-analysis  preformed  by  Anderson, 
Clouse,  Freedland  and  Lustman  (2001) 
provided  evidence  that,  even  when  gender, 
geographic  area,  diagnostic  criteria  for 
depression, and type of diabetes were controlled 
for, the odds of depression were twice as high 
in  those  with  diabetes  compared  to  control 
subjects. However, they did not control for the 
type of treatment or number of complications. 
The  authors  suggest  that  depression  has  a www.inernationaljournalofcaringsciences.org 
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negative  effect  on  ability  to  function  and 
adherence  to  medical  treatment,  as  well  as 
glycemic control, increasing the risk of diabetes 
complications. DeGroot et al. (2001) make the 
argument that, if depression is correlated with 
hyperglycemia and hyperglycemia is correlated 
with the complications of diabetes, there may 
be  a  correlation  between  depression  and 
complications of diabetes.  
 To  further  indicate  this,  a  meta-analysis  by 
Mezuk,  Eaton,  Albrecth  and  Golden  (2008) 
showed  that  those  with  depression  have  a  60 
percent  increased  risk  of  type  II  diabetes, 
however, type II diabetes only led to a subtle 
increase  in  risk  for  major  depression.  As  a 
meta-analysis, the authors could not control for 
duration  of  the  disease,  number  of 
complications, or type or amount of treatment 
for  either  depression  or  type  II  diabetes,  and 
were  limited  by  the  quality  of  the  research 
conducted.  It  has  been  suggested  that  other 
risks for depression may mask the occurrence 
of  depression in  type  II  diabetics.  It  has  also 
been suggested that it is difficult to screen for 
depression  in  older  adults,  especially  when 
brain  function  may  be  decreasing  due  to  age 
(Gallo, Anthony & Muthen, 1994). This meta 
analysis provides solid evidence that depression 
does  increase  risk  type  II  diabetes,  but  is 
ambiguous as to the relationship from type II 
diabetes to major depression. 
It would appear that major depression directly 
leads  to type  II  diabetes due  to physiological 
changes  in  serotonin  as  well  as  symptomatic 
lifestyle changes such as reduced exercise and 
reduced physical activity. The connection from 
type II diabetes to major depression, however, 
is  less  clear.  Although  higher  rates  of 
depression  have  been  found  among  diabetics 
(Anderson,  Clouse,  Freedland  &  Lustman, 
2001),  it  has  also  been  shown  that  those 
considered  pre-diabetic  and  diabetic  who 
weren’t  undergoing  any  treatment  had  lower 
rates of depression than non diabetics, and the 
only population which exhibited increased rates 
of  depression  was  diabetics  undergoing 
treatment (Golden et al., 2008). Other research 
indicates  that,  although  there  may  be  a  link 
from  type  II  diabetes  to  depression,  it  is  not 
significant  and  may  be  caused  by  extrinsic 
factors  (Mezuk,  Eaton,  Albrecht  &  Golden, 
2008). This raises the question as to whether the 
treatment  of  or  duration  of  diabetes  leads  to 
depression.  
The  reported  side  effects  of  hyperglycemia 
medication  include  diarrhea,  stomach  pain, 
constipation  and  heartburn.  Although  none  of 
these  side  effects  can  be  directly  associated 
with  depression,  they  contribute  to  patient 
burden and could be an integral component in 
the  connection  between  type  II  diabetes  and 
depression. 
The  stigmatisms  that  western  society  places 
upon chronic illness can be stressors in and of 
themselves. If one develops type II diabetes, not 
only  do  they  have  to  deal  with  treating  and 
monitoring their symptoms, but must constantly 
think of the disease during every day activities. 
Diabetes  also  comes  with  the  extra  worry 
regarding what other people are thinking about 
their actions. Each dietary and physical activity 
choice will be analyzed to a greater extent due 
to the constant stigmatism that type II diabetes 
carries  with  it. The  simple question ‘how  are 
you?’ becomes a complicated question when a 
chronic disease is present. The answer ‘fine’ is 
no  longer  applicable,  clearly  one  is  not  fine 
when they have developed a chronic lifestyle-
based  disease.  So  what  is  the  answer  to  that 
question?  “Fine,  considering  the 
circumstances”? or “More fine than yesterday”? 
Does one judge their level of ‘fine’ based on 
insulin  levels?  These  questions  and  concerns 
make  it  difficult  for  diabetics  to  enjoy  as 
enjoyable of a life. 
This question becomes even more complicated 
when  considering  a  person  suffering  from 
depression.  Since  the  disease  itself  brings  to 
question ones self-worth, it is entirely probable 
that a person with depression would suffer even 
more from social stigmatisms than a diabetic. 
As is evident, both type II diabetes and major 
depression carry with them heavy stigmatisms 
in today’s society. The comorbidity of the two 
only  increases  those  stigmatisms,  as  well  as 
results  in  decreased  adherence  to  treatments, 
decrease  functioning,  increased  costs  and 
decreased quality of life (Ciechanowski, Katon 
& Russo, 2000). 
While this connection has been recognized by 
professionals  and  in  the  literature,  few 
treatment modalities has been devised to treat www.inernationaljournalofcaringsciences.org 
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both conditions simultaneously. While evidence 
suggests  that  treating  depression  in  type  II 
diabetics may improve diabetic symptoms and 
increase  life  span,  this  treatment  modality  is 
geared  more  toward  depression,  not  both 
(Lustman, Freedland, Griffith & Clouse, 2000; 
Gallo, Bogner, Morales, Post, Have & Bruce, 
2005).  Furthermore,  all  pharmaceuticals 
developed specifically for comorbid depression 
and  diabetes  are  accompanied  by  side  effects 
which  cause  higher  drop  out  rates  and  lower 
adherence  to  the  medication,  worsening  the 
condition of both diseases.  
Since type II diabetes and depression are inter-
related, and represent a significant cost to both 
individuals and communities, the ideal financial 
and health-related option would be a treatment 
that could prevent the comorbidity of the two 
diseases  while  eliminating  the  need  for 
pharmaceutical  treatments.  By  applying  a 
treatment  to  a  diabetic  before  depression 
occurs,  one  could  possibly  stave  off  the 
development of the comorbid diseases, and vice 
versa with depressed patients. 
One treatment that has shown to be effective for 
both depression and type II diabetes separately 
is exercise (Sigal et al., 2007; Roth & Holmes, 
1987;  Steptoe,  Edwards,  Moses  &  Mathews, 
1989).  Furthermore,  exercise  does  not  come 
with  the  negative  side  effects  of  medication. 
Exercise  is  also  more  cost  effective  than 
medication, potentially only costing as much as 
a gym membership or personal trainer. While 
pharmaceuticals result in side effects including 
constipation,  weight  gain,  somnolence  and 
sexual  dysfunction  (Consumer  Reports  Best 
Buy  Drugs,  2011),  exercise  tends  to  result in 
side  effects  such  as  weight  loss,  improved 
mood,  increased  life  span,  improved  immune 
function,  strengthened  cardiovascular  system 
and  improved  self  image  (Blumenthal  et  al., 
1999;  Sigal  et  al.,  2007;  Sigal,  Wasserman, 
Kenny & Casteneda-Sceppa, 2004). One of the 
only potentially negative things about exercise 
is  the  time  requirement,  where  as  medication 
can  be taken in about a second. 
 
Exercise 
 
Exercise is a sub category of physical activity. 
While physical activity includes any movement 
produced by the contraction of skeletal muscle 
requiring  energy  expenditure,  exercise  is 
structured physical activity that one specifically 
sets  time  for  and  plans  in  advance,  with  the 
intention of maintaining or improving physical 
fitness (Sigal et al., 2004). Exercise can refer to 
either  aerobic  or  resistance  exercise.  Aerobic 
consists  of  muscular  endurance  and 
cardiovascular  fitness  exercise  whereas 
resistance training focuses on muscular strength 
and anaerobic fitness.  
 
Exercise and Type II Diabetes 
 
The  goal  when  treating  type  II  diabetes  is  to 
achieve  and  maintain  the  nearest  to  normal 
possible  blood  glucose  level  (Eastman  et  al., 
1993).  Exercise  has  been  shown  to  increase 
insulin sensitivity (Duncan et al., 2003), making 
it a logical, yet frequently overlooked treatment 
for type II diabetes. Both resistance and aerobic 
exercise could theoretically be equally good at 
treating  diabetes,  as  muscle  contraction 
stimulates  the  glucose  uptake  into  the  cell. 
Since  both  types  of  exercise  involve  muscle 
contraction, it is logical that both would result 
in  improved  glycemic  control.  Muscle 
contraction causes glucose receptors on the cell 
membrane to be expressed without the presence 
of  insulin.  Research  indicates  that  insulin 
mediated  and  contraction  mediated  glucose 
uptake  function  on  at  least  partially  separate 
pathways  (Ploug,  Galbo,  Vinen,  Jorgensen  & 
Richter, 1987). This allows glucose to enter the 
cell  without  the  presence  of  insulin  if 
contraction is present, and vice versa. Thus, in a 
person  that  has  developed  a  resistance  to 
insulin,  exercise  can  bypass  that  part  of  the 
process and provide cells with the glucose they 
need  to  function  (McArdle,  Katch  &  Katch, 
2007). 
Resistance  training  has  been  proposed  as  a 
treatment for type II diabetes because it tends to 
build  larger,  stronger  muscles  than  aerobic 
training. Muscle is the primary utilization site 
for glucose, so the more muscle one has, the 
more glucose can be removed from the blood 
stream,  and  utilized  in  the  cell  (Braith  & 
Stewart, 2006). While, theoretically, resistance 
training should improve glycemic control and 
glucose  tolerance,  some  research  has  shown 
that  it  has  limited  to  no  effect  on  either 
(Poehlman, Dvorak, DeNiro, Brochu & Ades, www.inernationaljournalofcaringsciences.org 
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2000; Banz, Maher, Thompson, Basset, Moore, 
Ashraf, Keefer & Zemel, 2003). Other research 
provides  evidence  that  it  produces  similar 
results  to  aerobic  exercise,  and  effectively 
reduces insulin resistance (Sigal et al., 2007). 
Furthermore,  there  is  research  supporting  the 
idea that improved blood glucose only occurs 
when  one  performs  resistance  training  at  70 
percent  or  higher  of  the  individual’s  one 
repetition maximum strength (1RM) (Braith & 
Stewart,  2006).  Other  research  suggests  that 
obese type II diabetics should not perform short 
term  high  intensity  exercises,  such  as  70 
percent  of  1RM,  due  to  the  idea  that  it  may 
actually  increase  blood  glucose  (Kjaer, 
Hollenbeck,  Frey-Hewitt,  Galbo,  Haskell  & 
Reaven, 1990). This conflicting literature would 
indicate  that,  while  resistance  training  has  its 
place in treating type II diabetes, more research 
is  necessary.  Until  consensus  is  reached,  it 
would be inefficient to use it exclusively. 
Aerobic exercise has been shown conclusively 
to  enhance  insulin  sensitivity  acutely  after 
exercise,  and  chronically  with  continuous 
training  (Rogers,  1989;  Walker,  Piers,  Putt, 
Jones & O’Dea, 1999). It is suggested that this 
increased  insulin  sensitivity  is  a  result  of 
increased  muscle  metabolism  as  well  as 
changes in body composition (Boule, Haddad, 
Kenny , Wells & Sigal, 2001; Tuomilehto et al., 
2001).  
Aerobic  exercise  has  been  shown  to  also 
decrease body weight, blood pressure and blood 
triglycerides, while increasing HDL cholesterol 
levels. Along with these, one of the effects of 
aerobic  training  is  reduced  insulin  resistance; 
some  studies  show  as  much  as  30  percent 
improvement in insulin action (Bogardus et al., 
1984). While light, moderate and high intensity 
aerobic  training  have  all  been  shown  to 
decrease  insulin  resistance,  sprint  interval 
exercise  has  not  been  shown  to  produce  a 
significant  difference  (Brestoff  et.  al,  2009). 
This may be due to the anaerobic qualities of 
sprinting, but may also be related to the short 
duration of sprinting.  
A key study by Sigal et al. (2007) showed that 
both  resistance  training  and  aerobic  training 
result in a significant decrease in blood glucose 
levels, and that a combination of the two result 
in an even larger decrease. It is mentioned by 
the  authors  that  the  greatest  reductions  were 
seen in those with higher baseline values, and 
that those  with  lower  baseline  glucose  values 
only  saw  significant  decreases  in  the 
combination  group.  During  the  course  of  the 
study,  almost  twice  as  many  members  of  the 
control  group  needed  to  increase  their  oral 
hyperglycemia  medication  when  compared  to 
members  of  the  resistance,  aerobic  and 
combination groups. In comparison, those in an 
exercise group were 1.3 to 2 times more likely 
than  the  control  group  to  decrease  or 
discontinue  oral  hyperglycemia  medications. 
Although  these  authors  concluded  that  the 
combination  therapy  was  the  most  beneficial, 
they did not take in to account the amount of 
time committed to each respective exercise. The 
combination  group  committed  twice  as  much 
time to exercise as the aerobic and resistance 
group, considering they had to perform a full 
regimen  of  both exercises. Having committed 
twice as much time, it is only logical that the 
members  of  this  group  would  see  greater 
improvements. 
With this information, it can be concluded that 
both  resistance  and  aerobic  exercise  are 
effective  treatment  modalities  for  type  II 
diabetes.  
It can also be concluded that, while both types 
of exercise are effective, a combination of the 
two is the most effective. 
 
Exercise and Major Depression 
 
Medication is the most common treatment for 
depression,  however,  exercise  has  been 
receiving  more  attention  lately  as  a  possible 
treatment  modality.  Most  studies  have  shown 
that  exercise  is  at  least  comparable  to 
medication  in  reducing  depression  levels 
(Blumenthal  et.  al,  1999).  The  effects  of 
exercise on depression are problematic to study, 
mainly  due  to  difficulty  associated  with 
recruiting  the  population.  One  of  the  most 
common  problems  encountered  with  using 
exercise as a treatment modality for depression 
is  that  the  subject  population  is  inherently 
unmotivated  to  exercise,  or  do  any  physical 
activity.  In  depression  patients,  adherence  to 
treatments  such  as  antidepressants  or  psycho-
therapy  is  low.  When  a  researcher  includes 
exercise, adherence drops even lower. Another www.inernationaljournalofcaringsciences.org 
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problem  arises  when  one  examines  the  social 
interactions that are bound to happen in a gym 
or fitness area setting. In the case of depression, 
a  person  is  already  suffering  from  a  mental 
condition where over sensitivity is a symptom, 
often  particularly  to  issues  regarding  body 
image.  When  others  are  brought  into  the 
equation, the situation becomes more stressful 
and more likely to cause the patient to withdraw 
further from society.  
While a gym setting may induce a withdrawn 
reaction from some individuals suffering from 
depression,  others  may  react  in  an  opposite 
manner. One of the benefits of exercise is that 
it’s  positively  viewed  both  by  the  rest  of 
society, and by the individual (Salmon, 2000). 
Humans, as a species, are genetically wired to 
view  exercise  as  a  positive  action.  From  an 
evolutionary perspective, it is not only positive, 
but necessary. Based on this theory, when one 
partakes  in  exercise,  it  will  raise  self-esteem 
and  body  image.  Exercise  may  also  elicit 
positive  feedback  from  peers  and  therefore 
increases  sense  of  worth  (Lawlor  &  Hopker, 
2001). Exercise could also potentially pose as a 
distraction  from  negative  thoughts  (Lepore, 
1997). As important as these social constructs 
may  be,  it  is  the  physiological  effects  of 
exercise that provide the greatest changes.  
It  is  unknown  exactly  how  exercise 
physiologically  affects  depression,  however, 
many  mechanisms  have  been  proposed. 
Changes  in  brain  chemistry  associated  with 
depression, for the most part, involve serotonin. 
It is well known that serotonin is linked with 
happiness  and  feelings  of  well-being  (Young, 
2007;  Neumeister,  Young  &  Stastny,  2004). 
Serotonin is generally released from cells three 
times a second if one is at rest. If one is in non-
rapid  eye  movement  (NREM)  sleep  then  that 
frequency  decreases,  and  if  REM  sleep  is 
occurring, serotonin-releasing cells are inactive. 
However,  if  one  is  active  the  release  rate 
increases to five or more per minute (Jacobs, 
1994).  Based  on  this  increase,  one  may  infer 
that  exercise  can  be  beneficial  to  those  with 
depression. Even if the synapses aren’t working 
properly  and  some  serotonin  is  being  re-
uptaken  into  the  original  cell,  when  exercise 
occurs, almost twice as much serotonin is being 
released, making it easier for the receiving cell 
to get the necessary serotonin. 
Unlike type II diabetes, resistance training and 
aerobic  training  have  shown  to  affect 
depression in a similar manner when used for 
treatment. Resistance training has been shown 
to  significantly  reduce  certain  measures  of 
depression, as well as improve quality of life 
and  social  functioning  (Singh,  Clements  & 
Fiatrone,  1996).  It  is  hypothesized  that  the 
increase in social functioning and quality of life 
may be in part responsible for the reduction in 
depression.  
Aerobic  exercise  has  shown  similar  results, 
providing  significant  reductions  in  depression 
in  a  short  amount  of  time  (Dimeo,  Bauer, 
Varahram, Proest & Halter, 2000). It has been 
suggested  that  aerobic  exercise  may  be  more 
effective  than  pharmaceuticals  as  a  treatment 
modality  for a  depressive  patient  beginning  a 
new treatment, as antidepressants take from two 
to four weeks to see any therapeutic effect.  
Based on these results, one can determine that 
both  resistance  and  aerobic  exercise  are 
effective  treatment  modalities  for  both 
depression and type II diabetes. If exercise is 
effective at treating both conditions, it can be 
concluded that it may be an effective treatment 
in preventing the comorbidity of the two. 
 
Discussion 
 
The literature agrees on the concept of exercise 
being  equally,  if  not  more,  effective  then 
pharmaceuticals at treating type II diabetes and 
major depression; especially in the cases of type 
II diabetes, in which part of the etiology is a 
sedentary  lifestyle.  Even  though  virtually  all 
research  and  clinical  specialists  agree  that 
exercise is an effective treatment modality for 
both  type  II  diabetes  and  major  depression, 
there is still a disconnect between the evidence 
and  the application.  It’s  been  established  that 
providing treatment for symptoms as opposed 
to etiology is not effective for chronic diseases 
such  as  type  II  diabetes  and  depression, 
however,  western  medicine  continues  to 
produce and apply treatments and medications 
that only provide relief from various symptoms 
instead of providing treatments for the cause of 
the disease, and often cause more problems in 
addition to the original pathology.  
It has been shown conclusively that exercise is www.inernationaljournalofcaringsciences.org 
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equally  as  good  as,  if  not  better  than, 
pharmaceuticals at treating both type II diabetes 
and  major  depression.  If  the  evidence  is 
pointing  to  exercise  as  an  effective,  non-
invasive treatment modality with no detrimental 
side effects, why is society still implementing 
pharmaceuticals as a first line treatment? Type 
II  diabetes  and major  depression  have  a  high 
rate of comorbidity that is only compounded by 
pharmaceutical  treatments.  Exercise  has  been 
shown to be effective at treating both diseases 
separately,  and  it  is  likely  that  it  would  be 
effective  at  treating  the  diseases  together, 
potentially preventing comorbidity.  
 
Future Research 
 
There is a great body of research regarding type 
II  diabetes,  depression,  and  their  resulting 
comorbidity.  There  have  also  been  many 
studies performed on the effects of exercise on 
both depression and type II diabetes. Although 
the etiologies of each respective condition are 
not completely clear, the research in this field 
can provide the reader with a moderately clear 
understanding  of  how  type  II  diabetes  and 
major depression are connected and how they 
affect  each  other.  Research  indicates  the 
medications for treating hyperglycemia may be 
a  cause  of  depression  in  type  II  diabetics.  A 
study  should  be  conducted  regarding  the 
occurrence  of  depression  in  type  II  diabetics 
being treated with pharmaceuticals and type II 
diabetics  being  treated  with  exercise.  A 
complete  understanding  of  neurotransmitters 
and  their  effect  on  depression  would  also  be 
beneficial to the scientific community, as well 
as  a  deeper  examination  of  insulin  resistance 
and the factors that play in to it. 
 
Conclusion 
 
It’s been established that exercise is effective 
for both type II diabetes and depression (Sigal 
et  al.,  2007;  Roth  &  Holmes,  1987;  Steptoe, 
Edwards, Moses & Mathews, 1989). If it is at 
least  as  good  or  better  than  the  majority  of 
medications for each condition, and carries with 
it no detrimental side effects, it is sensible to 
use it as a first line treatment modality. It’s also 
been established that type II diabetes can lead 
to depression, and that depression can lead to 
type II diabetes. Since the comorbidity of the 
diseases is so prevalent in today’s society, one 
would  think  that  treatment  modalities  would 
gear  toward  the  prevention  and  treatment  of 
both  diseases  simultaneously.  However, 
western  medicine  insists  on  treating  them  as 
separate conditions. Evidence points to the idea 
that  it  may,  in  fact,  be  the  respective 
medications  that  cause  this  link  between  the 
two  diseases.  Whether  or  not  medication  is 
solely responsible for the connection between 
type II diabetes and depression, it clearly plays 
a  role  in  the  comorbidity  and  results  in 
unwanted side effects. Although it is sometimes 
difficult to motivate those with chronic illness 
to exercise, lifestyle change such as increased 
exercise is the only way in which effective long 
term changes will occur. Pharmaceuticals focus 
on symptomatic treatment and therefore are not 
appropriate  for  inducing  long  term  changes. 
Exercise should be implemented as a first line 
treatment  modality  for  those  with  type  II 
diabetes  and  major  depression  in  order  to 
prevent the comorbidity of the two diseases and 
treat the etiology of the original pathology. 
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Appendix 
Table 1 
Drug  Treats  Side effects  Cost 
Tricyclic 
Antidepressant 
Depression, 
pain, 
insomnia 
Dry  mouth,  blurred  vision,  cardiac  arrhythmias, 
sedation,  urinary  retention,  constipation,  postural 
hypertension, addiction, seizures, hypertension 
Around  $60  per 
month 
 
Anticonvulsant  Depression, 
pain 
Dizziness,  headache,  edema,  weight  gain,  rash, 
coordination  problems  such  as  speech  and 
concentration,  nausea,  dry  mouth,  blurry  vision, 
nervousness,  anorexia,  liver  failure,  suicidal 
thoughts 
Anywhere  from 
$4  to  $860  per 
month 
Selective 
Serotonin 
Reuptake 
Inhibitor 
Depression, 
pain 
Sexual  dysfunction,  appetite  change,  dizziness, 
lethargy,  headache,  agitation,  generalized  pain, 
nausea, depression, metabolism inhibition, anxiety, 
sleep  disturbance,  insomnia,  gastrointenstinal 
disturbances,  weight  gain,  withdrawal  after 
discontinuation 
Around  $150  per 
month,  ranging 
from $20 to $500  
Seretonin-
Norepinephrine 
Reuptake 
Inhibitor 
Depression, 
obesity 
Nausea, dry mouth, dizziness, insomia, somnolence, 
constipation,  increased  blood  pressure,  excessive 
sweating,  sexual  dysfunction,  erectile  dysfunction, 
increased  heart  rate,  heart  palpitation,  urinary 
retention,  headache,  anxiety,  changes  in  appetite, 
blurred vision, withdrawal after discontinuation 
Anywhere  from 
$50  to  $540  per 
month,  usually 
slightly over $100 
Monoaimine 
Oxidase Inhibitor 
Depression  Insomnia,  sedation,  hypotension,  sexual 
dysfunction,  hypomania,  weight  gain,  edema, 
hypertension,  muscle  spasm,  withdrawal  after 
discontinuation 
n/a 
Tetracyclic 
Antidepressant 
Depression, 
pain, 
insomnia 
Dry mouth, dizziness, reduced seizure threshold  Anywhere  from 
$40  to  $200  per 
month 
 
 